U.S. markets close in 3 hours 10 minutes

Lipidor AB (publ) (LIPI.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
14.98-0.04 (-0.27%)
At close: 5:29PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.02
Open15.02
Bid14.54 x N/A
Ask14.98 x N/A
Day's Range14.46 - 15.02
52 Week Range9.49 - 20.16
Volume132,314
Avg. Volume115,889
Market Cap425.386M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.70
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

      Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.

    • PR Newswire

      Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis

      Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for commencement of the Phase III study. As Lipidor has previously announced, the main purpose of the study is to compare the therapeutic efficacy of AKP02 with existing medicines for mild to moderate psoriasis. Results from the study are expected in the first half of 2022.

    • PR Newswire

      Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology

      Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery technology AKVANO® in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions. Lipidor receives a royalty of 15-17.5% on future product sales. When a predetermined accumulated sales volume is achieved, Lipidor will receive an additional milestone payment in the form of 1% of the share capital value of Cannassure, up to a maximum of EUR 350,000. Lipidor's projection is that this milestone compensation will be paid within a two-year period.